MX2023013892A - Analogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibicion de la helicasa recq del sindrome de werner (wrn). - Google Patents
Analogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibicion de la helicasa recq del sindrome de werner (wrn).Info
- Publication number
- MX2023013892A MX2023013892A MX2023013892A MX2023013892A MX2023013892A MX 2023013892 A MX2023013892 A MX 2023013892A MX 2023013892 A MX2023013892 A MX 2023013892A MX 2023013892 A MX2023013892 A MX 2023013892A MX 2023013892 A MX2023013892 A MX 2023013892A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- inhibiton
- wrn
- triazolo
- treating diseases
- Prior art date
Links
- 102000019196 RecQ Helicases Human genes 0.000 title 1
- 108010012737 RecQ Helicases Proteins 0.000 title 1
- 201000011032 Werner Syndrome Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical class BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona un compuesto, o una sal farmacéuticamente aceptable del mismo, de la fórmula (I): (ver Fórmula) (I) en donde R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K y A han sido descriptos en la presente, usos terapéuticos de dichos compuestos, usos de dichos compuestos como químicos de investigación, una composición farmacéutica y combinaciones que comprenden dichos compuestos, y métodos para elaborar los compuestos de la invención.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021096104 | 2021-05-26 | ||
| CN2022085537 | 2022-04-07 | ||
| PCT/IB2022/054850 WO2022249060A1 (en) | 2021-05-26 | 2022-05-24 | Triazolo-pyrimidine analogues for treating diseases connected to the inhibiton of werner syndrome recq helicase (wrn) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013892A true MX2023013892A (es) | 2023-12-11 |
Family
ID=82019774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013892A MX2023013892A (es) | 2021-05-26 | 2022-05-24 | Analogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibicion de la helicasa recq del sindrome de werner (wrn). |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11878973B2 (es) |
| EP (1) | EP4347596A1 (es) |
| JP (1) | JP2024522345A (es) |
| KR (1) | KR20240013168A (es) |
| CN (1) | CN117425657A (es) |
| AR (1) | AR125966A1 (es) |
| AU (1) | AU2022279728A1 (es) |
| BR (1) | BR112023024551A2 (es) |
| CA (1) | CA3219799A1 (es) |
| CL (1) | CL2023003489A1 (es) |
| CO (1) | CO2023018119A2 (es) |
| CR (1) | CR20230616A (es) |
| DO (1) | DOP2023000256A (es) |
| EC (1) | ECSP23095674A (es) |
| IL (1) | IL308229A (es) |
| MX (1) | MX2023013892A (es) |
| PE (1) | PE20240587A1 (es) |
| TW (1) | TW202313616A (es) |
| UY (1) | UY39786A (es) |
| WO (1) | WO2022249060A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210371855A1 (en) * | 2018-06-15 | 2021-12-02 | Ideaya Biosciences, Inc. | Methods of inhibiting proliferative cells |
| TW202417450A (zh) * | 2022-10-12 | 2024-05-01 | 瑞士商諾華公司 | 三環化合物及其用途 |
| WO2024105553A1 (en) * | 2022-11-16 | 2024-05-23 | Novartis Ag | Bicyclic heterocycles and their use as wrn inhibitors |
| US20240197715A1 (en) | 2022-11-18 | 2024-06-20 | Novartis Ag | Pharmaceutical combinations and uses thereof |
| WO2024110853A1 (en) | 2022-11-23 | 2024-05-30 | Novartis Ag | Solid forms of a fused pyridine for the treamtent of cancer |
| WO2024120378A2 (en) * | 2022-12-05 | 2024-06-13 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Triazole compounds, preparation methods and medicinal uses thereof |
| WO2024140597A1 (zh) * | 2022-12-30 | 2024-07-04 | 苏州浦合医药科技有限公司 | Wrn解旋酶抑制剂 |
| CN118271323A (zh) * | 2022-12-30 | 2024-07-02 | 苏州浦合医药科技有限公司 | Wrn抑制剂 |
| WO2024153155A1 (zh) * | 2023-01-18 | 2024-07-25 | 成都微芯药业有限公司 | 双杂环wrn抑制剂、其制备方法及其应用 |
| WO2024155884A1 (en) * | 2023-01-20 | 2024-07-25 | Synnovation Therapeutics, Inc. | Heterocyclic compounds as wrn inhibitors |
| WO2024153244A1 (zh) * | 2023-01-20 | 2024-07-25 | 南京再明医药有限公司 | 含氮类化合物 |
| WO2024187049A1 (en) * | 2023-03-08 | 2024-09-12 | Synnovation Therapeutics, Inc. | Heterocyclic compounds as wrn inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| JP2010502644A (ja) * | 2006-08-29 | 2010-01-28 | トラスティーズ オブ ボストン ユニバーシティ | Ｗｒｎ結合分子を用いる治療方法 |
| US8173661B2 (en) | 2006-11-08 | 2012-05-08 | The Rockefeller University | Alpha-IIB-beta-3 inhibitors and uses thereof |
| CN102439011B (zh) * | 2009-02-11 | 2016-05-04 | 加利福尼亚大学校务委员会 | Toll样受体调节剂和疾病的治疗 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| WO2018229683A1 (en) * | 2017-06-15 | 2018-12-20 | Novartis Ag | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
| US11530413B2 (en) | 2017-07-21 | 2022-12-20 | Novartis Ag | Compositions and methods to treat cancer |
| WO2019236448A1 (en) * | 2018-06-04 | 2019-12-12 | The Broad Institute, Inc. | Therapeutic treatment of microsatellite unstable cancers |
| US20210371855A1 (en) * | 2018-06-15 | 2021-12-02 | Ideaya Biosciences, Inc. | Methods of inhibiting proliferative cells |
| WO2020033413A2 (en) | 2018-08-07 | 2020-02-13 | Tosk, Inc. | Modulators of ras gtpase |
| WO2020041756A1 (en) | 2018-08-23 | 2020-02-27 | Foghorn Therapeutics Inc. | Methods of treating cancer |
| CN112409331B (zh) | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| CN112778311B (zh) * | 2019-11-01 | 2024-06-04 | 上海翰森生物医药科技有限公司 | 含氮并环类衍生物抑制剂、其制备方法和应用 |
-
2022
- 2022-05-24 CA CA3219799A patent/CA3219799A1/en active Pending
- 2022-05-24 PE PE2023003130A patent/PE20240587A1/es unknown
- 2022-05-24 AU AU2022279728A patent/AU2022279728A1/en active Pending
- 2022-05-24 AR ARP220101380A patent/AR125966A1/es unknown
- 2022-05-24 BR BR112023024551A patent/BR112023024551A2/pt unknown
- 2022-05-24 TW TW111119316A patent/TW202313616A/zh unknown
- 2022-05-24 MX MX2023013892A patent/MX2023013892A/es unknown
- 2022-05-24 EP EP22729790.0A patent/EP4347596A1/en active Pending
- 2022-05-24 IL IL308229A patent/IL308229A/en unknown
- 2022-05-24 UY UY0001039786A patent/UY39786A/es unknown
- 2022-05-24 KR KR1020237044267A patent/KR20240013168A/ko unknown
- 2022-05-24 CN CN202280035572.6A patent/CN117425657A/zh active Pending
- 2022-05-24 CR CR20230616A patent/CR20230616A/es unknown
- 2022-05-24 JP JP2023572685A patent/JP2024522345A/ja active Pending
- 2022-05-24 WO PCT/IB2022/054850 patent/WO2022249060A1/en active Application Filing
- 2022-05-25 US US17/824,407 patent/US11878973B2/en active Active
-
2023
- 2023-11-22 DO DO2023000256A patent/DOP2023000256A/es unknown
- 2023-11-23 CL CL2023003489A patent/CL2023003489A1/es unknown
- 2023-12-21 CO CONC2023/0018119A patent/CO2023018119A2/es unknown
- 2023-12-21 EC ECSENADI202395674A patent/ECSP23095674A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022249060A1 (en) | 2022-12-01 |
| BR112023024551A2 (pt) | 2024-02-15 |
| CA3219799A1 (en) | 2022-12-01 |
| CR20230616A (es) | 2024-05-06 |
| TW202313616A (zh) | 2023-04-01 |
| KR20240013168A (ko) | 2024-01-30 |
| DOP2023000256A (es) | 2024-01-31 |
| UY39786A (es) | 2023-01-31 |
| PE20240587A1 (es) | 2024-03-21 |
| CN117425657A (zh) | 2024-01-19 |
| ECSP23095674A (es) | 2024-01-31 |
| CL2023003489A1 (es) | 2024-06-28 |
| US11878973B2 (en) | 2024-01-23 |
| AR125966A1 (es) | 2023-08-30 |
| AU2022279728A1 (en) | 2023-11-16 |
| IL308229A (en) | 2024-01-01 |
| JP2024522345A (ja) | 2024-06-18 |
| US20230046859A1 (en) | 2023-02-16 |
| CO2023018119A2 (es) | 2023-12-29 |
| EP4347596A1 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013892A (es) | Analogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibicion de la helicasa recq del sindrome de werner (wrn). | |
| JOP20210307A1 (ar) | مثبطات جسيم التهابي nlrp3 | |
| GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| CR20200488A (es) | Péptidos macrocíclicos contra actinetobacter baumannii | |
| WO2021147236A9 (zh) | 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用 | |
| UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
| EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
| MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| EA200970535A1 (ru) | Антибактериальные производные хинолина | |
| MX2009003874A (es) | Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos. | |
| MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
| MX2021012223A (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria. | |
| MX2022006333A (es) | Compuesto triheterociclico como inhibidor de jak y uso del mismo. | |
| EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
| MX2023013683A (es) | Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| PH12019502652A1 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
| MX2023012039A (es) | Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos. | |
| SE0303480D0 (sv) | Benzofuranes | |
| MX2024002409A (es) | Terapias contra el cancer. | |
| MX2022008487A (es) | Degradadores de smarca2-vhl. | |
| EA202192760A1 (ru) | Трициклические соединения | |
| MX2020009287A (es) | Nuevo compuesto y composicion farmaceutica que lo comprende. | |
| NO20081736L (no) | Antitumormidler |